Vectra® Study Published in the Journal Current Medical Research & Opinion
February 22 2019 - 7:05AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in
personalized medicine, today announced the publication of an
important clinical study regarding its Vectra
®
test in Current Medical Research & Opinion. The key finding is
that the Vectra test (MBDA) was nearly three times better at
predicting radiographic progression (i.e., new joint damage) than
DAS28-CRP or CRP in people with rheumatoid arthritis (RA).
This study evaluated data from five cohorts in four studies to
establish the relationship between the Vectra score and risk for
radiographic progression (RP). The analysis included data from 929
patients with RA who received conventional DMARDs alone or with
adalimumab, infliximab or abatacept. In every cohort, RP was most
frequent among patients with a high Vectra score (>44) compared
with patients with a low/moderate Vectra score (≤44). In addition,
the study showed that patients with high Vectra scores were 4.6
times as likely as patients with low/moderate Vectra scores to
develop RP (p<0.001) and was three times more predictive than
traditional disease activity measures of DAS28-CRP or CRP (Figure
1).
“These findings suggest that the Vectra test is the best single
method for identifying patients at risk of joint damage. When
combined with a physician’s clinical assessment, the molecular
information provided by Vectra can be used to modify treatments
appropriately to avoid irreversible joint damage for their
patients,” said Elena Hitraya, M.D., Ph.D., rheumatologist and
chief medical officer at Myriad Autoimmune. "The consistency of
data from multiple studies on the ability of Vectra to predict RP,
compared to traditional measures of disease activity, provides
strong evidence that Vectra represents an advance in patient
care."
Vectra is the leading personalized medicine test for patients
with RA. The clinical performance of Vectra has been demonstrated
in more than 35 publications. Three out of four rheumatologists
have used Vectra and have ordered it for more than 425,000 of their
patients. Vectra has been included in clinical guidelines used by
United Rheumatology and Bendcare and is being considered for
inclusion in the American College of Rheumatology
guidelines.
About Rheumatoid ArthritisRheumatoid arthritis
is an autoimmune disease that mainly attacks the body’s joints,
leading to significant morbidity and financial burden.
Approximately 60 percent of people with inadequately treated RA are
unable to work 10 years after onset. The American College of
Rheumatology estimates that RA affects 1.3 million people in the
United States.
About VectraVectra is a multi-biomarker
molecular blood test that provides an objective and personalized
measure of inflammatory disease activity in patients with
rheumatoid arthritis. Vectra provides unsurpassed ability to
predict radiographic progression and helps guide medical management
decisions to improve patient outcomes. Vectra testing is performed
at a state-of-the-art CLIA (Clinical Laboratory Improvement
Amendments) facility. Test results are reported to the physician
five to seven days from shipping of the specimen. Physicians can
receive test results by fax or the private web portal, VectraView.
For more information on Vectra, please visit: www.vectrada.com.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on five
strategic imperatives: build upon a solid hereditary cancer
foundation, growing new product volume, expanding reimbursement
coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate 2020. For
more information on how Myriad is making a difference, please visit
the Company's website: www.myriad.com. Follow Myriad on
Twitter via @MyriadGenetics.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris,
Foresight and Prequel are trademarks or registered trademarks of
Myriad Genetics, Inc. or its wholly owned subsidiaries in the
United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor StatementThis press release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements related to the Vectra test significantly outperforming
DAS28-CRP and CRP; the Vectra test being the best predictor of
joint damage in patients with rheumatoid arthritis; the information
provided by Vectra being used to modify treatments and avoid
irreversible joint damage for their patients; Vectra representing
an advance in patient care; potential inclusion of Vectra in the
American College of Rheumatology guidelines; and the Company's
strategic directives under the caption "About Myriad Genetics."
These "forward-looking statements" are based on management's
current expectations of future events and are subject to a number
of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied
by forward-looking statements. These risks and uncertainties
include, but are not limited to: the risk that sales and profit
margins of our molecular diagnostic tests and pharmaceutical and
clinical services may decline; risks related to our ability to
transition from our existing product portfolio to our new tests,
including unexpected costs and delays; risks related to decisions
or changes in governmental or private insurers’ reimbursement
levels for our tests or our ability to obtain reimbursement for our
new tests at comparable levels to our existing tests; risks related
to increased competition and the development of new competing tests
and services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services and any future tests and services are terminated
or cannot be maintained on satisfactory terms; risks related to
delays or other problems with operating our laboratory testing
facilities and our healthcare clinic; risks related to public
concern over genetic testing in general or our tests in particular;
risks related to regulatory requirements or enforcement in the
United States and foreign countries and changes in the structure of
the healthcare system or healthcare payment systems; risks related
to our ability to obtain new corporate collaborations or licenses
and acquire new technologies or businesses on satisfactory terms,
if at all; risks related to our ability to successfully integrate
and derive benefits from any technologies or businesses that we
license or acquire; risks related to our projections about our
business, results of operations and financial condition; risks
related to the potential market opportunity for our products and
services; the risk that we or our licensors may be unable to
protect or that third parties will infringe the proprietary
technologies underlying our tests; the risk of patent-infringement
claims or challenges to the validity of our patents or other
intellectual property; risks related to changes in intellectual
property laws covering our molecular diagnostic tests and
pharmaceutical and clinical services and patents or enforcement in
the United States and foreign countries, such as the Supreme Court
decision in the lawsuit brought against us by the Association for
Molecular Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; the risk that we may be unable to comply with
financial operating covenants under our credit or lending
agreements; the risk that we will be unable to pay, when due,
amounts due under our credit or lending agreements; and other
factors discussed under the heading "Risk Factors" contained in
Item 1A of our most recent Annual Report on Form 10-K for the
fiscal year ended June 30, 2018, which has been filed with the
Securities and Exchange Commission, as well as any updates to those
risk factors filed from time to time in our Quarterly Reports on
Form 10-Q or Current Reports on Form 8-K. All information in this
press release is as of the date of the release, and Myriad
undertakes no duty to update this information unless required by
law.
Media Contact: |
Ron Rogers (801)
584-3065 rrogers@myriad.com |
Investor Contact: |
Scott Gleason(801)
584-1143sgleason@myriad.com |
An image accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/999bdeee-a0c0-4aac-96c3-521a40a9b250
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024